Reg. No.										

MANIPAL UNIVERSITY

M. PHARM. PART–I DEGREE EXAMINATION – MAY/JUNE 2010

SUBJECT: APPLIED PHARMACOTHERAPEUTICS – I (PPR 601)

(SPECIALIZATION: PHARMACY PRACTICE)

Thursday, May 27, 2010

Time: 10:00 – 13:00 Hrs. Max. Marks: 100

✍ **Answer ALL questions.**

1A. Explain various dialysis methods in the management of renal failure.

1B. Explain mechanisms of any four drug induced hematological disorders.

(10+10 = 20 marks)

2A. Define asthma and enumerate trigger factors for asthma.

2B. Differentiate chronic bronchitis and emphysema and explain the management of chronic bronchitis.

2C. Mention the DSM IV criteria for anxiety disorders.

(6+8+6 = 20 marks)

3A. Mention the signs and symptoms and discuss the management of Alzheimer's disease.

3B. Classify epilepsy and explain the management of tonic-clonic seizures.

(10+10 = 20 marks)

4A. Enumerate various sleep disorders and explain the management of Insomnia.

4B. Describe various complications of chronic renal failure and explain the management of any three.

4C. Explain the role of fibrates and statins in hyperlipidemia.

(6+8+6 = 20 marks)

5A. Describe the positive and negative symptoms of schizophrenia.

5B. Explain the management of bipolar disorder.

5C. Explain the management of hypertension in Pregnancy and Hypertensive Emergency.

(6+6+8 = 20 marks)

Reg. No.										

MANIPAL UNIVERSITY

M. PHARM. PART–I DEGREE EXAMINATION – MAY/JUNE 2010

SUBJECT: APPLIED PHARMACOTHERAPEUTICS – II (PPR 602)

(SPECIALIZATION: PHARMACY PRACTICE)

Friday, May 28, 2010

Time: 10:00 – 13:00 Hrs. Max. Marks: 100

Answer ALL questions.

1A. Discuss the algorithm for the management of type 2 diabetes.

1B. Mention signs and symptoms of hyperthyroidism. Explain the management of the same.

(10+10 = 20 marks)

2A. Describe the clinical manifestation and management of pulmonary tuberculosis.

2B. Enumerate various complications of cerebral Malaria and its management.

(12+8 = 20 marks)

3A. Explain the pathogenesis and management of peptic ulcer disorder by NASIDs and H.Pylori infection.

3B. Discuss the general prescribing guidelines for drug use in pediatrics.

(12+8 = 20 marks)

4A. Mention the diagnostic criteria for rheumatoid arthritis bases on American Rheumatism Association and explain the role of DMRDs in the management of the same.

4B. Enumerate the various types of drug induced liver disorder and explain the mechanism of any two examples of causative agents.

(12+8 = 20 marks)

5A. Draw the Gompertizian Kinetics tumor growth curve with respect to symptoms and diagnosis.

5B. Explain the role of beta-adrenoreceptor antagonists in the management of glaucoma.

5C. Discuss the general principles of antiretroviral therapy and mention three HAART regimens with their dose.

(5+5+10 = 20 marks)

Reg. No.										

MANIPAL UNIVERSITY

M. PHARM. PART–I DEGREE EXAMINATION – MAY/JUNE 2010

SUBJECT: CLINICAL AND HOSPITAL PHARMACY (PPR 603)

(SPECIALIZATION: PHARMACY PRACTICE)

Saturday, May 29, 2010

Time: 10:00 – 13:00 Hrs. Max. Marks: 100

✍ **Answer ALL questions.**

1A. Define clinical pharmacy services and explain the goals of procedure of following two services:

i) Provision of Drug information

ii) Liaison with community services

1B. Discuss various communication skills required for Medication counseling.

((6+6)+8 = 20 marks)

2A. Enumerate various pharmacoepidemiological methods and explain any two methods with its advantage and disadvantage.

2B. Describe quality assurance programme for clinical pharmacy services.

((2+8)+10 = 20 marks)

3A. Mention complete blood count with its normal values and differentiate microcytic anemia with macrocytic anemia using lab values.

3B. Explain importance of any four parameters of urine analysis.

((9+6)+5 = 20 marks)

4A. Define pharmacy therapeutic committee and discuss its role in the hospitals.

4B. What is unit dose drug distribution system and explain it with its advantages.

((2+10)+8 = 20 marks)

5. **Write briefly on:**

5A. Rational drug use

5B. Poly pharmacy and its implications

5C. Sch N requirement

5D. OTC drugs

(5×4 = 20 marks)

Reg. No.										

MANIPAL UNIVERSITY

M. PHARM. PART–I DEGREE EXAMINATION – MAY/JUNE 2010

SUBJECT: DRUG DISCOVERY DEVELOPMENT AND CLINICAL RESEARCH (PPR 604)

(SPECIALIZATION: PHARMACY PRACTICE)

Monday, May 31, 2010

Time: 10:00 – 13:00 Hrs. Max. Marks: 100

Answer ALL questions.

1A. Explain various sources of lead generation and the role of high throughput screening in drug discovery.

1B. Describe the Toxicity studies during preclinical drug testing.

1C. Enumerate various approaches to drug discovery and explain anyone method.

(10+6+4 = 20 marks)

2A. Enumerate and explain the essential components of a clinical trial protocol.

2B. Explain the procedure for critical evaluation of quantitative and qualitative reviews.

(10+10 = 20 marks)

3A. Describe the composition and responsibilities of IRB/IEC.

3B. Explain the process for safety reporting of serious adverse events in clinical trials.

3C. Describe the methods for data security in clinical trials.

(10+5+5 = 20 marks)

4A. Explain the role of principal investigator with respect to premature termination of trial, communication with IRB/IEC, records and reports and compliance with protocol.

4B. Define clinical trial. Discuss various phases in clinical trials.

(10+10 = 20 marks)

5. **Write briefly on:**

5A. ICH-GCP principles

5B. Clinical research associate

5C. Informed consent process

5D. Regulatory requirements for clinical trials in USA and Europe

(5×4 = 20 marks)

Reg. No.										

MANIPAL UNIVERSITY

M. PHARM. PART–I DEGREE EXAMINATION – MAY/JUNE 2010

SUBJECT: CLINICAL PHARMACOKINETICS, TOXICOLOGY AND BIOSTATISTICS (PPR 605)

(SPECIALIZATION: PHARMACY PRACTICE)

Tuesday, June 01, 2010

Time: 10:00 – 13:00 Hrs. Max. Marks: 100

✍ **Answer ALL questions.**

1A. Discuss various factors which affecting the absorption of a drug.

1B. Describe one compartment open model for IV bolus administration.

(10+10 = 20 marks)

2A. Define renal clearance and explain the factors affecting renal clearance.

2B. Explain the different factors affecting protein binding of a drug with suitable examples.

2C. Explain the causes of nonlinear pharmacokinetics with suitable examples.

(20 marks)

3A. Define bioavailability and explain in vivo methods for bioavailability testing.

3B. What is nonlinear pharmacokinetics? Explain the causes of nonlinearity.

(15+5 = 20 marks)

4A. Discuss the general principles involved in the management of poisoning.

4B. Explain the clinical symptoms and management of Organophosphorus and Paracetamol Poisoning.

(10+10 = 20 marks)

5A. Enumerate various parametric tests for significance. Explain the tests used to compare the means of different populations.

5B. Explain the importance of Null hypothesis in statistical testing.

5C. Explain enterohepatic circulation of drug and its clinical significance.

(10+5+5 = 20 marks)